SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd. announced that CARE Ratings Limited has reaffirmed its ratings on various bank facilities, including Long Term Bank Facilities at CARE A; Stable, with the outlook revised from Positive, and Short Term Bank Facilities at CARE A1, alongside enhancements to the Long Term Bank Facilities from 350.87 to 570.07; CARE Ratings also noted a disclaimer pertains to ratings issued and content published, and indicated a surveillance/review is possible annually, with ratings subject to revision or withdrawal based on periodic review. Additionally, the rating agency provided details regarding Term Loans from Export Import Bank of India (amounts of 180.00 and 95.00), Term Loans from Axis Bank Ltd. (38.38), IDBI Bank Ltd. (13.75 and 1.96), State Bank of India (8.38, 2.24), Export Import Bank of India (6.37 and 2.99), and various Fund Based Limits and Standby Lines of Credit from State Bank of India, IDBI Bank Ltd., RBL Bank Limited, Letters of Credit, Bank Guarantees, and Credit Exposure Limits, all totaling facilities of 622.90, while CareEdge Ratings acknowledged that the ratings reflect opinions as on the date of the rating, and CARE Ratings Ltd. has also indicated that the issuer is not cooperating.

SMS Pharmaceuticals Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the company's 38th Annual General Meeting, previously scheduled for Wednesday, September 23, 2026, will now be held on Tuesday, September 29, 2026, via video conferencing or other audio-visual means, with a record date for dividend eligibility set for Tuesday, September 22, 2026, and a book closure from Wednesday, September 23, 2026, to Tuesday, September 29, 2026.

SMS Pharmaceuticals Limited (NSE: SMSPHARMA; BSE:532815) announced its unaudited financial results for the quarter ended June 30, 2026, reporting revenue from operations of Rs 207.0 crore, a 6% year-over-year increase driven by broad-based growth across high-value APIs. The company’s profit after tax increased 8% year-over-year to Rs 20.20 crore, while maintaining an EBITDA margin of 20%, and the board approved an infusion of up to Rs 50 crore as a loan into its subsidiary, SMS Peptides Private Limited, to establish a dedicated peptide R&D facility.

SMS Pharmaceuticals Ltd share price declined 5.65% to Rs 373.75 after the company's net profit slipped by 3.63% to Rs 20.2 crore, while revenue from operations reduced 13.02% to Rs 206.96 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, rising 6%. It has improved by 2.79% over last one week and rallied by 15.59% in last one month while the market capitalization of SMS Pharmaceuticals Ltd has eased by 1.73% and 7.50% in the same period respectively. Profit before tax (PBT) of SMS Pharmaceuticals Ltd stood at Rs 27.21 crore in Q2 FY26, rising by 11.65% year-on-year, and gaining 0.52% quarter-on-quarter. EBITDA came in at Rs 39 crore, easing 1.11% YoY and gaining 5.04% sequentially. Total expenses reduced by 15.46% to Rs 176.0 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 136.65 crore, posting a minor increase of 6.38% YoY, while employee benefits expense was at Rs 23.54 crore, tumbling by 20.12% YoY. For the TTM ended FY26, revenue from operations rose 10.36% to Rs 782.75 crore, while net profit jumped 36.99% to Rs 67.4 crore, compared to previous TTM. EBITDA surged by 11398% to Rs 132.77 crore, and PBT witnessed a strong rise of 39.68% to Rs 92.34 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 81.71 crore in FY26, as against Rs 50.12 crore in FY25. SMS Pharmaceuticals Ltd rallied 57.57% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.

SMS Pharmaceuticals Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the Board of Directors meeting, previously scheduled for August 1, 2026, has been rescheduled to July 31, 2026, to consider and approve the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026. The company also stated that the trading window for its equity shares will be closed from July 1, 2026, to August 2, 2026, and will reopen on August 3, 2026, in accordance with SEBI regulations.

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 1 August 2026.

SMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 0.4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.

Net profit of SMS Pharmaceuticals rose 60.97% to Rs 32.71 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales declined 4.13% to Rs 237.95 crore in the quarter ended March 2026 as against Rs 248.20 crore during the previous quarter ended March 2025. For the full year,net profit rose 47.51% to Rs 101.99 crore in the year ended March 2026 as against Rs 69.14 crore during the previous year ended March 2025. Sales rose 13.30% to Rs 886.87 crore in the year ended March 2026 as against Rs 782.75 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales237.95248.20 -4 886.87782.75 13 OPM %16.7716.44 -19.3117.76 - PBDT37.2037.16 0 156.56126.67 24 PBT27.0728.52 -5 116.6492.34 26 NP32.7120.32 61 101.9969.14 48 Powered by Capital Market - Live

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Total operating expenses for the period under review aggregated to Rs 166.80 crore, up 19.0% YoY. PBIDT improved by 34.1% to Rs 47.40 crore in Q3 FY26 from Rs 35.34 crore in Q3 FY25. Profit before tax in Q3 FY26 stood at Rs 31.16 crore, up by 38.9% from Rs 22.44 crore recorded in Q3 FY25. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag. Powered by Capital Market - Live